Skip to main content

Prograf and Alcohol/Food Interactions

There are 2 alcohol/food/lifestyle interactions with Prograf (tacrolimus).

Major

Tacrolimus Food/Lifestyle

Major Food Interaction

GENERALLY AVOID: Grapefruit and/or grapefruit juice may increase the plasma concentrations of tacrolimus. The proposed mechanism for the interaction is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. Although clinical data are lacking, this interaction may result in increased risk of serious adverse reactions such as nephro- and neurotoxicity, as well as other adverse effects associated with tacrolimus such as malignancies, infections, diabetes, hyperkalemia, hypertension, and QT prolongation.

GENERALLY AVOID: Alcohol may modify the rate of tacrolimus release from extended release formulations, thereby potentially increasing the risk of serious adverse reactions.

ADJUST DOSING INTERVAL: Coadministration with food decreases the rate and extent of tacrolimus absorption. This effect is greatest after a high-fat meal.

MANAGEMENT: Patients should avoid consumption of food or drink containing grapefruit during treatment with tacrolimus. Concomitant use of tacrolimus, especially extended release formulations, with alcohol should also be avoided. Tacrolimus extended release formulations should be administered on an empty stomach, at least 1 hour before or 2 hours after a meal, and tacrolimus immediate release formulations should be taken consistently every day with or without food.

References (18)
  1. (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
  2. Hooks MA (1994) "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother, 28, p. 501-11
  3. (2022) "Product Information. Adoport (tacrolimus)." Sandoz Ltd
  4. (2024) "Product Information. TACrolimus (Sandoz) (TACrolimus)." Sandoz Pty Ltd
  5. (2023) "Product Information. Prograf (tacrolimus)." Astellas Pharma US, Inc
  6. (2023) "Product Information. Astagraf XL (tacrolimus)." Astellas Pharma US, Inc
  7. (2025) "Product Information. Envarsus XR (tacrolimus)." Veloxis Pharmaceuticals
  8. (2024) "Product Information. Prograf (tacrolimus)." Astellas Pharma Canada Inc
  9. (2024) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Canada Inc
  10. (2024) "Product Information. Envarsus PA (tacrolimus)." Endo Operations LTD
  11. (2024) "Product Information. Dailiport (tacrolimus)." Sandoz Ltd
  12. (2025) "Product Information. Prograf (tacrolimus)." Astellas Pharma Ltd
  13. (2025) "Product Information. Envarsus (tacrolimus)." Chiesi Ltd
  14. (2025) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Ltd
  15. (2025) "Product Information. Modigraf (tacrolimus)." Astellas Pharma Ltd
  16. (2024) "Product Information. Advagraf XL (TACrolimus)." Astellas Pharma Australia Pty Ltd
  17. (2024) "Product Information. proGRAF (TACrolimus)." Astellas Pharma Australia Pty Ltd
  18. (2024) "Product Information. TACrolimus XR (Sandoz) (TACrolimus)." Sandoz Pty Ltd

Switch to consumer interaction data

Moderate

Tacrolimus High Blood Pressure (Hypertension)

Moderate Potential Hazard, Moderate plausibility

tacrolimus - hypertension

The use of tacrolimus has been associated with hypertension. Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure. Close monitoring of blood pressure is recommended.

References (1)
  1. (2001) "Product Information. Prograf (tacrolimus)." Fujisawa

Switch to consumer interaction data

Prograf drug interactions

There are 884 drug interactions with Prograf (tacrolimus).

Prograf disease interactions

There are 7 disease interactions with Prograf (tacrolimus) which include:


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.